213 related articles for article (PubMed ID: 25251901)
1. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment.
von Scholten BJ; Lajer M; Goetze JP; Persson F; Rossing P
Diabet Med; 2015 Mar; 32(3):343-52. PubMed ID: 25251901
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes.
von Scholten BJ; Hansen TW; Goetze JP; Persson F; Rossing P
J Diabetes Complications; 2015 Jul; 29(5):670-4. PubMed ID: 25935863
[TBL] [Abstract][Full Text] [Related]
3. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.
Kumarathurai P; Anholm C; Fabricius-Bjerre A; Nielsen OW; Kristiansen O; Madsbad S; Haugaard SB; Sajadieh A
J Hypertens; 2017 May; 35(5):1070-1078. PubMed ID: 28129251
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial.
Skov J; Pedersen M; Holst JJ; Madsen B; Goetze JP; Rittig S; Jonassen T; Frøkiaer J; Dejgaard A; Christiansen JS
Diabetes Obes Metab; 2016 Jun; 18(6):581-9. PubMed ID: 26910107
[TBL] [Abstract][Full Text] [Related]
5. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials.
Wang B; Zhong J; Lin H; Zhao Z; Yan Z; He H; Ni Y; Liu D; Zhu Z
Diabetes Obes Metab; 2013 Aug; 15(8):737-49. PubMed ID: 23433305
[TBL] [Abstract][Full Text] [Related]
6. Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Kanaoka T; Tamura K; Moriya T; Tanaka K; Konno Y; Kondoh S; Toyoda M; Umezono T; Fujikawa T; Ohsawa M; Dejima T; Maeda A; Wakui H; Haku S; Yanagi M; Mitsuhashi H; Ozawa M; Okano Y; Ogawa N; Yamakawa T; Mizushima S; Suzuki D; Umemura S
Clin Exp Hypertens; 2011; 33(4):255-63. PubMed ID: 21699452
[TBL] [Abstract][Full Text] [Related]
7. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial.
von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P
Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731
[TBL] [Abstract][Full Text] [Related]
8. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes.
Lovshin JA; Barnie A; DeAlmeida A; Logan A; Zinman B; Drucker DJ
Diabetes Care; 2015 Jan; 38(1):132-9. PubMed ID: 25414155
[TBL] [Abstract][Full Text] [Related]
9. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.
Fonseca VA; Devries JH; Henry RR; Donsmark M; Thomsen HF; Plutzky J
J Diabetes Complications; 2014; 28(3):399-405. PubMed ID: 24561125
[TBL] [Abstract][Full Text] [Related]
10. Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.
Zobel EH; von Scholten BJ; Lindhardt M; Persson F; Hansen TW; Rossing P
J Diabetes Complications; 2017 Jan; 31(1):162-168. PubMed ID: 27769801
[TBL] [Abstract][Full Text] [Related]
11. The effect of liraglutide on renal function: A randomized clinical trial.
von Scholten BJ; Persson F; Rosenlund S; Hovind P; Faber J; Hansen TW; Rossing P
Diabetes Obes Metab; 2017 Feb; 19(2):239-247. PubMed ID: 27753201
[TBL] [Abstract][Full Text] [Related]
12. Effect of lacidipine, a dihydropyridine calcium antagonist on renal function of hypertensive patients with renal insufficiency.
Bailey RR; Shand BI; Smith AH; Robson RA; Lynn KL
Clin Nephrol; 1997 Oct; 48(4):224-9. PubMed ID: 9352156
[TBL] [Abstract][Full Text] [Related]
13. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study.
Faber R; Zander M; Pena A; Michelsen MM; Mygind ND; Prescott E
Cardiovasc Diabetol; 2015 Apr; 14():41. PubMed ID: 25896352
[TBL] [Abstract][Full Text] [Related]
14. Effect of liraglutide on ambulatory blood pressure in patients with hypertension and type 2 diabetes: A randomized, double-blind, placebo-controlled trial.
Liakos A; Lambadiari V; Bargiota A; Kitsios K; Avramidis I; Kotsa K; Gerou S; Boura P; Tentolouris N; Dimitriadis G; Tsapas A
Diabetes Obes Metab; 2019 Mar; 21(3):517-524. PubMed ID: 30242948
[TBL] [Abstract][Full Text] [Related]
15. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
16. LEADER-4: blood pressure control in patients with type 2 diabetes and high cardiovascular risk: baseline data from the LEADER randomized trial.
Petrie JR; Marso SP; Bain SC; Franek E; Jacob S; Masmiquel L; Leiter LA; Haluzik M; Satman I; Omar M; Shestakova M; Van Gaal L; Mann JF; Baeres FM; Zinman B; Poulter NR;
J Hypertens; 2016 Jun; 34(6):1140-50. PubMed ID: 26855018
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
Joergensen C; Tarnow L; Goetze JP; Rossing P
Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
[TBL] [Abstract][Full Text] [Related]
18. Varying patterns of the antihypertensive and antialbuminuric response to higher doses of renin-angiotensin-aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients.
Weir MR; Hollenberg NK; Remuzzi G; Zappe DH; Meng X; Parving HH
J Hypertens; 2011 Oct; 29(10):2031-7. PubMed ID: 21841500
[TBL] [Abstract][Full Text] [Related]
19. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
Theilade S; Hansen TW; Goetze JP; Rossing P
Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
[TBL] [Abstract][Full Text] [Related]
20. Effect of liraglutide on blood pressure: a meta-analysis of liraglutide randomized controlled trials.
Zhao X; Huang K; Zheng M; Duan J
BMC Endocr Disord; 2019 Jan; 19(1):4. PubMed ID: 30616638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
